Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation

Chinese Journal of Cardiology

Volumn 40, Issue 1, 2012, Pages 25-29

  Guan, Shao Yi ^a   Han, Ya Ling ^a   Li, Yi ^a   Guo, Liang ^b   Yang, Bai Song ^b   Wang, Shou Li ^a   Jing, Quan Min ^a   Wang, Xiao Zeng ^a   Ma, Ying Yan ^a   Liu, Xiao Dong ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b NONE

Author keywords

Coronary disease; Platelet aggregation inhibitors; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CILOSTAZOL; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY STENT; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; AGED; ASPIRIN; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE;

EID: 84862107369     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2012.01.006     Document Type: Article

References (16)

1. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003, 107: 2908-2913.
2. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets, 2004, 15: 95-99.
3. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost, 2006, 4: 542-549.
4. Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet, 2011, 378: 1071-1078.
5. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358: 527-533.
6. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol, 2007, 50: 1822-1834.
7. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010, 303: 754-762.
8. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol, 2010, 56: 919-933.
9. Geisler T, Grass D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost, 2008, 6: 54-61.
10. Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J, 2008, 156: 1080-1088.
11. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol, 2008, 51: 1404-1411.
12. Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev, 2001, 19: 369-386.
13. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol, 2009, 53: 1101-1109.
14. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011, 305: 1097-1105.
15. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of cilostazol-based triple antiplatelet therapy on ischemic complication after drug-eluting stent implantation) trial. J Am Coll Cardiol, 2011, 57: 280-289.
16. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 2011, 306: 1215-1523.